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Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been iso-
lated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine 
(OPV). Patients may excrete poliovirus strains for months or years; the excreted viruses 
are frequently highly divergent from the parental OPV and have been shown to be 
as neurovirulent as wild virus. Thus, these patients represent a potential reservoir 
for transmission of neurovirulent polioviruses in the post-eradication era. In support 
of WHO recommendations to better estimate the prevalence of poliovirus excreters 
among PIDs and characterize genetic evolution of these strains, 635 patients including 
570 with primary antibody deficiencies and 65 combined immunodeficiencies were 
studied from 13 OPV-using countries. Two stool samples were collected over 4 days, 
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tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen 
patients (2%) excreted polioviruses, most for less than 2 months following identification 
of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficien-
cies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 
patients (4.7%). Patients with combined immunodeficiencies had increased risk of 
delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV 
was detected in subjects with combined immunodeficiencies in a short period of time 
after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion 
among PID patients should be reinforced until polio eradication is certified and the 
use of OPV is stopped. Survival rates among PID patients are improving in lower and 
middle income countries, and iVDPV excreters are identified more frequently. Antivirals 
or enhanced immunotherapies presently in development represent the only potential 
means to manage the treatment of prolonged excreters and the risk they present to the 
polio endgame.
Keywords: poliovirus eradication, immunodeficiency-associated vaccine-derived polioviruses, oral poliovirus 
vaccine, humoral immunodeficiency, combined immunodeficiency, primary immunodeficiency
inTrODUcTiOn
Primary immunodeficiencies (PIDs) are a heterogeneous group of 
inherited disorders due to developmental defects or dysfunction 
of the immune system components (1). PID patients can poten-
tially be infected by immunizations if they receive live vaccines 
(2). Attenuated oral poliovirus vaccine (OPV) immunization has 
been associated with poliovirus infection in patients with primary 
antibody deficiencies and combined immunodeficiencies, which 
can lead to paralysis (3–5).
Paralysis is not the only risk of OPV immunizations in PID 
patients since some vaccinated PID patients may shed vaccine-
derived polioviruses (VDPVs) due to a prolonged period of 
intestinal replication. VDPV variants of OPV serotypes (PV1, 
PV2, and PV3) show increased nucleotide divergence in the 
viral protein 1 (VP1) coding region associated with increased 
neuropathogenicity (6). Although neonatal screening has 
begun to expedite the early diagnosis of patients with severe 
combined immunodeficiencies (SCIDs) and agammaglobu-
linemia to modify their vaccination program and therapeutic 
management, these screening tests do not diagnose T or B cell 
dysfunction, nor have they been implemented worldwide. On 
the other hand, approximately 150 countries still use OPV in the 
national childhood immunization schedule, which can spread 
and be transmitted to PID patients incidentally. Approximately 
100 VDPV infections have been reported in PID patients world-
wide to date (4, 7, 8). As a potential reservoir for neurovirulent 
VDPV strains, infected PID patients represent a global risk to 
unimmunized contacts and to the Global Polio Eradication 
Initiative (4, 9).
The significant impact of OPV on the elimination of poliomy-
elitis due to wild poliovirus (WPV) and its additional beneficial 
properties (e.g., economic costs, easy administration, and supe-
rior mucosal antibody response) are evident. However, because 
WPV type 2 has been eradicated and 90% of circulating VDPV, 
and approximately 40% of VAPP cases are caused by type 2, type 
2 was removed from OPV in all countries globally in April 2016. 
As a result, screening for immunodeficiency-associated VDPV 
(iVDPV) shedding of known PID patients is more critical 
to completing elimination of live type 2 poliovirus from the 
world (10, 11).
Thus, assessing the risk associated with prolonged iVDPV 
excretion among PID patients by estimating the prevalence 
in a worldwide study is of critical importance for stakeholders 
and decision-makers to build an effective strategy for the polio 
endgame, including development of potential treatments such 
as antivirals. Based on several reports showing that not only 
patients with primary antibody deficiencies but also combined 
immunodeficiencies are very susceptible to persistent polio and 
non-polio enterovirus (NPEV) infections (4, 12), this multicenter 
study has been designed to determine the prevalence of iVDPV in 
patients with both types of immunodeficiencies and characterize 
the genetic properties of associated virus strains.
MaTerials anD MeThODs
Patients
All patients enrolled in this study were diagnosed with PID 
from 19 Jeffrey Modell Foundation (JMF) sites in 13 OPV-using 
countries from January 2014 to November 2015 (Table  1). 
Inclusion criteria encompassed patients 6 weeks of age or greater 
and having a diagnosis of SCID, combined immunodeficiency, 
agammaglobulinemia, or common variable immunodeficiency 
(CVID). Other types of PID patients were not included in this 
study.
Assessment of each patient at the different JMF sites met 
the updated criteria introduced by the European Society for 
Immunodeficiencies1 (13) and/or the American Academy of 
1 http://esid.org/Working-Parties/Registry/Diagnosis-criteria.
Table 1 | 19 Jeffrey Modell Foundation sites from 13 countries enrolled PID patients.
countrya city site no.b enrolled patients culture results national polio vaccinationc PiD screening
India Chandigarh Site 30 23 23 5 OPV doses (birth-6w-10w-14w-16m) No
Tunisia Tunis Site 12 40 40 1 IPV dose (6m) No
7 OPV doses (2m-3m-6m-18m-6y-12y-18y)
China Shanghai Site 23 52 51 4 OPV doses (2m-3m-4m-4y) No
Hong Kong Site 21 11 11 6 OPV doses before 2007 (birth-3m-5m-18m-6y-11y) No
Colombia Medellin Site 24 25 25 5 OPV doses (2m-4m-6m-18m-5y) No
Iran Tehran Site 14 102 102 6 OPV doses (birth-2m-4m-6m-18m-6y) No
Mexico Mexico City Site 25 20 20 2 OPV doses (>6m-<5y) No
Poland Warsaw Site 17 29 29 3 IPV doses (3m-5m-16m) No
1 OPV dose (6y)
Russia Moscow Site 18 35 35 2 IPV doses (3m-4.5m) No
4 OPV doses (6m-18m-20m-14y)
Moscow Site 28 20 20
Yekaterinburg Site 19 28 28
Turkey Ankara Site 27 30 29 2 IPV doses (2m-4m) No
2 OPV doses (6m-18m)
Ankara Site 26 43 43
Izmir Site 11 75 75
Istanbul Site 20 24 24
Israel Tel Hashomer Site 29 24 24 2 OPV doses (6m-18m) No
Japan Tokyo Site 13 9 8 2 OPV doses before 2012 (3m-18m) No
OPV, oral poliovirus vaccine; IPV, inactivated polio vaccine; PID, primary immunodeficiency; w, weeks; m, months; y, years.
aCountries are organized in order of World Bank income classification (lower middle, upper middle, and upper income).
bSite numbers are provided to correspond with subject numbers in Tables 3 and 4.
cWHO vaccine-preventable diseases: monitoring system. 2016 Global summary.
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Allergy, Asthma & Immunology for the diagnosis of PID (14). 
In all studied cases, other defined secondary causes of immu-
nodeficiency were excluded. Other types of PID patients were 
not included in this study. The standard criteria for diagnosis 
of patients were summarized in Table S1 in Supplementary 
Material.
Written informed consent (if 18  years of age or older), 
assent (if 7–17 years of age) or consent from the parents/guard-
ian (for those less than 7  years) was obtained, in accordance 
with the principles of the ethics committees or Institutional 
Review Board of the local institutes using common forms 
designed by The Task Force for Global Health (TFGH, protocol 
no: CVE-001, WIRB® Protocol #20130957; Data Sheet S1 in 
Supplementary Material) translated to the participant JMF 
sites’ local languages.
study Design
Each selected JMF study site identified patients who met the 
inclusion criteria at the time of enrollment. After collecting 
consent or assent forms, the JMF study site collected the relevant 
information to complete the patient’s log (to track enrollment 
and to maintain the link between the unique identifiers) and case 
report form (CRF), and assigned a coded identification number 
(ID) under a standardized procedure. IDs, names, and contact 
information was recorded in the patient’s log, which was stored 
securely at the site until completion of the study. All specimens 
and CRFs were labeled with ID only and not any personal 
identifiers. The CRF included region (country based on JMF site), 
demographic characteristics (including date of birth and gender), 
clinical features (type of PID, age of onset and medical records 
including signs or symptoms of poliovirus infection), polio vac-
cination history (date of first and last OPV exposure and type 
of exposure), PID treatment modalities, and specimen collection 
information.
Each JMF study site chose the optimal procedure for collection 
of two stool samples (about 8 g using provided kits) over a 4-day 
period depending on the proximity of the patient to the JMF 
study site, the practicality of patient travel to the study site and 
the availability of adequate cold storage of the stool sample (Table 
S2 in Supplementary Material).
After collection, the stool samples were kept refrigerated at 
a temperature of 2–8°C and shipped to the local or regional 
Global Polio Laboratory Network (GPLN) laboratory along with 
supporting documentation. The JMF study site provided an elec-
tronic copy of the CRF by encrypted means (using a secure FTP 
server at TFGH) to Centers for Disease Control and Prevention 
(CDC) for secure data management. Stool specimens were sent 
to the GPLN laboratory for isolation of poliovirus and NPEVs. 
Isolates were sent to the CDC polio/enterovirus laboratory 
using standard shipping protocols for further characterization 
and genomic sequencing. GPLN member laboratories in all six 
WHO regions followed standardized protocols to identify and 
Table 2 | Demographic data summary for all 635 PID patients.
Parameters all patients cViD agammaglobulinemia sciD Mhc class ii deficiency
Number of patients 635 320 250 54 11
Gender (M/F) 444/191 179/141 237/13 24/30 4/7
Current age, mean; years (SD) 12.7 (8.2) 21.1 (15.7) 18.0 (8.5) 3.8 (4.9) 7.9 (7.8)
Age at first OPV dose, mean; years (SD) 0.6 (0.8) 0.5 (1.6) 0.4 (1.2) 1.0 (2.6) 0.6 (0.9)
Age at last dose, mean; years (SD) 2.3 (2.0) 4.3 (4.9) 3.0 (3.6) 2.2 (3.4) NA
Exposure to OPV (Y/N) 584/51 303/17 233/17 37/17 11/0
Paralytic disease 14 4 10 0 0
OPV, oral poliovirus vaccine; CVID, common variable immune deficiency; SCID, severe combined immunodeficiency; PID, primary immunodeficiency; MHC, major histocompatibility 
complex.
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isolate poliovirus and NPEV. They also differentiated the three 
poliovirus serotypes, Sabin-like poliovirus, and vaccine derived 
(VDPV). For VDPVs, they conducted genomic sequencing to 
determine how long the virus had been circulating or had been 
excreted in the case of iVDPV excreters. This was done by com-
paring the nucleotide sequence of the VP1 region of the genome 
from PV isolates according to published protocols (15, 16). The 
number of mutations compared to the parent Sabin strain is 
approximately proportional to the duration of excretion. The 
accepted definition of an iVDPV is >1% nucleotide divergence 
from Sabin types 1 and 3 or >0.6% for Sabin type 2 in the VP1 
coding region (6).
If testing results were positive for poliovirus or NPEV, the JMF 
site physician assured that family members were appropriately 
vaccinated against polio and educated about principles of good 
hygiene to prevent fecal–oral transmission. The physician also 
followed-up any patient found to be excreting poliovirus periodi-
cally (every 1–2 months) until the cessation of excretion and the 
procedures for testing and reporting above were followed each 
time. Patients were considered as having cleared an infection 
if two consecutive stool specimens in 2  months were negative 
according to the WHO-recommended surveillance standard of 
poliomyelitis.2
The TFGH study manager ensured coordination of speci-
men shipment along with the JMF scientific program director, 
and laboratory results were communicated to CDC both by the 
GPLN laboratory through the GPLN global coordinator and by 
the TFGH study manager and entered into the secure database 
at CDC.
statistical analysis
Statistical analysis was performed using a commercially avail-
able software package (SPSS Statistics 17.0.0, SPSS, Chicago, IL, 
USA). The one-sample Kolmogorov–Smirnov test was applied 
to estimate whether data distribution is normal. Parametric and 
non-parametric analyses were performed based on the finding of 
this evaluation. A p-value of 0.05 or less was considered statisti-
cally significant.
2 http://www.who.int/immunization/monitoring_surveillance/burden/vpd/
surveillance_type/active/poliomyelitis_standards/en/.
resUlTs
characteristics of studied PiD cases and 
OPV Vaccination
During the study period, a total of 635 patients (444 males and 
191 females) were included into this study. CVID was the most 
common diagnosis of studied patients (n =  320) followed by 
agammaglobulinemia (n = 250), SCID (n = 54) and combined 
immunodeficiency [n = 11; all with a diagnosis of major histo-
compatibility complex (MHC) class II deficiency]. Age at time of 
study enrollment was 21.1 ± 15.7 years (mean ± SD) for patients 
with CVID, 18.0 ± 8.5 years for patients with agammaglobuline-
mia, 7.9 ±  7.8 years for patients with MHC class II deficiency, 
and 3.8 ± 4.9 years for SCID patients. None of the patients with 
SCID or MHC class II deficiency were transplanted prior to the 
study entry.
Among all enrolled patients from these OPV-using countries, 
44 individuals did not receive OPV vaccination based on the 
prior family history of PID and early diagnosis or modified 
inactivated polio vaccine-based national childhood immuniza-
tion schedule (Table 2). However, the median age at first OPV 
dose was approximately 2 months (range from birth to 6 years) 
for the 584 patients who did receive OPV. Past medical history 
of paralytic disease was identified in 14 patients (1.25% of CVID 
and 4% of agammaglobulinemia patients), but none of the SCID 
or MHC class II deficiency cases had a history of paralytic dis-
ease. Agammaglobulinemia patients were younger than SCID 
and CVID patients when they received their last dose of OPV, 
consistent with the cessation of further OPV doses after an earlier 
clinical diagnosis of PID (Table 2).
Use of intravenous and subcutaneous 
immunoglobulin
The majority (97%) of enrolled subjects were receiving either 
intravenous immune globulin (IVIG) or subcutaneous immune 
globulin (SCIG) while participating in the study. For 19 subjects, 
no IVIG or SCIG use was noted.
Frequency of Poliovirus and nPeV 
isolation
Thirteen patients (2%) excreted poliovirus with most patients 
excreting for less than 2  months following identification of 
infection (Table  3). The median age of poliovirus-excreting 
Table 3 | Data summary for all 13 PID patients with isolated poliovirus.
Patient iD gender age at study 
entry
Diagnosis siteb Most recent 
known OPV 
exposure
Virus excretion duration—no. of nucleotide changes
12-017 F 7 years CVID Tunisia 6 years Sabin 1 1 month—3 nucleotide changes
12-007a M 11 years MHC II deficiency Tunisia 1 month Sabin 2 5 months excretion—9 nucleotide changes (0.9%)
12-025 F 7 years MHC II deficiency Tunisia Unknown Sabin 3 1 month—3 mutations
14-057 M 6 years Agammaglobulinemia Iran 1 week Sabin 2 1 month—no mutations
14-108a F 10 months MHC II deficiency Iran 6 months Sabin 2 10 months excretion on study—12 nucleotide 
changes (1.2%)
14-116a M 3 months SCID Iran 2 months Sabin 2 6 nucleotide changes (0.6%)
14-117a F 1 year SCID Iran 6 months Sabin 2 10 nucleotide changes (1%)
26-012 M 22 years CVID Ankara, Turkey 7 years Sabin 2 <3 months—no nucleotide changes
27-030 F 2.5 years MHC II deficiency Ankara, Turkey 2 years Sabin 3 Sequence pending
20-003 M 8 months Agammaglobulinemia Istanbul, Turkey 6 months Sabin 2 5 months excretion on study—3–4 nucleotide 
changes
11-031a F 11 months SCID Izmir, Turkey 6 months Sabin 3 15 nucleotide changes
19-021 M 13 years CVID Yekaterinburg, 
Russia
5 years Sabin 3 No nucleotide changes
19-023 F 6.5 years Agammaglobulinemia Yekaterinburg, 
Russia
Not known Sabin 2 No nucleotide changes
OPV, oral poliovirus vaccine; CVID, common variable immune deficiency; SCID, severe combined immunodeficiency; M, male; F, female; PID, primary immunodeficiency;  
MHC, major histocompatibility complex.
aPatients with immunodeficiency-associated vaccine-derived polioviruses (iVDPV).
bCountries are organized in order of World Bank income classification (lower middle and upper middle income).
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patients was 6.5 years (range 3 months–22 years). Patients with 
combined immunodeficiencies (three SCID and four MHC 
class II deficiency) were at 10-fold increased risk of excreting 
poliovirus (10.7%) compared to patients with predominantly 
antibody defects (1.0%; three CVID and three agammaglobu-
linemia; p < 0.001). The average age of patients with combined 
immunodeficiencies excreting poliovirus was significantly lower 
than in antibody deficient patients (3.3 ± 3.0 vs. 9.2 ± 7.3 years; 
p = 0.044). None of these 13 patients were coinfected with NPEV. 
Poliovirus excretion was not observed in any of patients with a 
history of paralytic disease.
Non-polio enteroviruses were isolated from 4.7% of evalu-
ated patients (17 CVID, 8 agammaglobulinemia, 2 SCID, and 
3 MHC class II deficiency), with a higher prevalence of NPEV 
infection in MHC class II deficient patients compared to 
patients with other forms of PIDs (p = 0.012; Figure 1). There 
was no difference in NPEV prevalence by gender (5.1% of 
males and 3.6% of females). Table  4 summarizes the clinical 
and virologic information for NPEV excreters. Echoviruses 
were the most commonly isolated virus (41%), followed by 
coxsackieviruses (24%).
The mean age of poliovirus excreting patients was signifi-
cantly lower than NPEV excreters (5.9 ± 4.3 vs. 10.4 ± 9.2 years, 
p =  0.005). Samples from nine patients (1.4% of 635 studied 
patients) were collected at the time of PID diagnosis and prior 
to administration of immunoglobulin replacement therapy. Of 
note, two of these nine cases (22.2%) were NPEV positive, both 
were diagnosed with antibody deficiency and were from the same 
center (12-006 and 12-019; p = 0.06). No poliovirus was isolated 
from these nine patients.
Predominance of iVDPV among combined 
immunodeficiency
Five (0.8% of all patients) of 13 poliovirus-excreting patients were 
considered iVDPV excreters based on the number of VP1 nucleo-
tide changes (median of 10 nucleotide changes; range, 6–15). Of 
note, all iVDPV excreters had combined immunodeficiency (three 
SCID and two MHC class II deficiency), and four of these five 
patients excreted Sabin 2 strains (Table 3). The median number 
of mutations did not differ between SCID (1%; range 0.6–1.5%) 
and MHC II deficiency (1.05%; range, 0.9–1.2%) patients. None 
of the iVDPV excreters presented with acute flaccid paralysis, but 
chronic diarrhea was a common clinical manifestation. OPV vac-
cination had occurred in all of iVDPV excreters, and the median 
time from the first OPV dose to identification of iVDPV was 
10 months (range 3 months–11 years). The sequence divergence 
suggests that secondary exposure may have been the source of 
infection in some cases. Further vaccination was avoided in all 
patients due to the diagnosis of PID.
clinical Presentation and genetic studies 
of iVDPV excreters
One MHC class II deficiency patient (12-007) was followed for 
several years prior to enrollment in the current study showing 
intermittent VDPV excretion episodes and reinfection with 
various VDPV strains and with several NPEV from a sibling 
FigUre 1 | Prevalence of enterovirus excreters among different groups of primary immunodeficiency patients. C, common variable immunodeficiency; M, major 
histocompatibility complex II deficiency; A, agammaglobulinemia; S, severe combined immunodeficiencies.
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and from the community (17). During the current study, he was 
infected with Sabin 2 strain (Table 3). The second MHC class II 
patient (14-108) was a 10-month-old girl with disseminated 
granulomatous disease (BCGosis) after BCG vaccination at age 
4 months who excreted poliovirus for 5 months. The mutation 
in CIITA gene (homozygous c.3242-3244delACA, p.Asn1082del) 
was confirmed in this patient using targeted PID genes panel 
sequencing.
The only Sabin serotype-3 iVDPV excreter was a girl with 
SCID (11-031; RAG1 c.1682G>A, p.R561H) enrolled at age 
11 months. This poliovirus had the highest number of nucleotide 
changes (15 nucleotides) observed in the study. Virus elimination 
was evident 3 months after hematopoietic stem cell transplanta-
tion. Two other SCID patients infected by serotype-2 iVDPV 
had the molecular diagnosis confirmed with a mutation in ADA 
(14-116; homozygous c.415G>T, p.Glu139X) and a mutation in 
RAG1 (14-117; homozygous c.1180C>T, p.Arg394Trp) genes, 
respectively.
DiscUssiOn
Primary immunodeficiency patients having defects in humoral 
or cellular immunity are at risk of chronic/prolonged infection 
with enteroviruses, including polioviruses. These patients can 
excrete iVDPV after receiving OPV or after being exposed to a 
household or community contact excreting poliovirus. Patients 
who are excreting polioviruses are at risk of developing paralytic 
poliomyelitis. Such patients must be identified, and their infection 
resolved, to protect the patients and achieve global eradication of 
poliovirus. The present study brings together the JMF network, 
TFGH, WHO, and CDC to estimate the prevalence of poliovirus 
excretion in selected PID patients who have been exposed to 
OPV. Two of the participant countries are high income (Israel 
and Japan); the remainder are lower (two countries) or upper 
(seven countries) middle income countries according to the 
World Bank classification. Three poliovirus excreters were from a 
lower middle income country (Tunisia), and the remainder were 
from upper middle income countries. NPEVs were isolated from 
patients from countries from all three economic strata.
Although few cross-sectional studies have been conducted to 
identify iVDPV among PID patients without paralysis (12, 17–21), 
this study identified the largest number of PID patients both 
with antibody and combined immune deficiencies. This study 
also constituted a large number of countries with worldwide dis-
tribution from four continents (Asia, Africa, Europe, and South 
America). Approximately 2% of the studied PID patients excreted 
Table 4 | Data summary for all 30 PID patients with isolated non-polio enteroviruses (NPEVs).
Patient iD gender age at study entry (year) Diagnosis siteb class of nPeV
12-031 M 5 MHC II deficiency Tunisia NA
12-037 M 0.4 MHC II deficiency Tunisia NA
12-006a M 5 CVID Tunisia Negative/E2
15-014 M 10 XLA Argentina E25
23-003 M 7 Agammaglobulinemia China NA
23-004 M 14 Agammaglobulinemia China NA
24-020 M 22 CVID Columbia NA
24-023 M 4 Agammaglobulinemia Columbia NA
14-079 F 28 CVID Iran EV11
14-020 M 7 Agammaglobulinemia Iran EV20
14-019 M 41 CVID Iran EV6
14-121 M 17 CVID Iran NA
25-020 M 8 CVID Mexico NA
25-019a M 8 Agammaglobulinemia Mexico NA
27-021 F 2 MHC II deficiency Ankara, Turkey CA5/no second sample
20-025 M 1 Agammaglobulinemia Istanbul, Turkey EV9
20-007 F 18 CVID Istanbul, Turkey CA4
20-006 M 20 CVID Istanbul, Turkey EV 33
11-018 M 5 SCID Izmir, Turkey CA10
11-050 F 6 CVID Izmir, Turkey CA2
11-048 M 0.5 CVID Izmir, Turkey CB
11-042 M 11 CVID Izmir, Turkey CB4
11-016 M 17 CVID Izmir, Turkey E6
11-075 F 0.7 CVID Izmir, Turkey NA
11-068 M 7 CVID Izmir, Turkey E7
29-012 F 3 Agammaglobulinemia Israel CB5
29-006 F 12 SCID Israel EV01
29-016 M 5 CVID Israel EV11
29-024 M 20 Agammaglobulinemia Israel EV13
29-008 M 9 Agammaglobulinemia Israel NA
OPV, Oral poliovirus vaccine; CVID, common variable immune deficiency; SCID, severe combined immunodeficiency; M, male; F, female; CA, coxsackie A virus; CB, coxsackie B 
virus; EV, enterovirus; E, echovirus; PID, primary immunodeficiency; MHC; major histocompatibility complex.
aSamples were collected prior to immunoglobulin replacement therapy.
bCountries are organized in order of World Bank income classification (lower middle, upper middle, and upper income).
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poliovirus. PID survival rates are improving in lower and mid-
dle income countries (22). Furthermore, iVDPV excreters are 
being identified at a markedly increased rate due to improved 
surveillance that includes polio symptom-free excreters (3). This 
reinforces the need for enhanced surveillance of PID patients 
until polio eradication is certified and the use of OPV is stopped. 
The findings of this study could help estimate the prevalence of 
iVDPV excreters, which is needed to assess the global risk to 
eradication posed by these excreters. Undiagnosed PID patients 
and cases with delayed diagnosis should be considered as poten-
tial contributors to underestimation.
In 5% of the studied patients, NPEV was isolated, and none 
of them were concomitantly excreting poliovirus. Although this 
prevalence was lower than in a previously reported single-center 
study (20%) (12), it demonstrates the susceptibility of patients 
with humoral and cellular immunodeficiency to prolonged excre-
tion of all enteroviruses. Higher prevalence of NPEV compared 
to OPV strains might be due to the multiplicity of circulating 
NPEV serotypes. Moreover, immunoglobulin preparations 
used for treatment of PID patients do not contain high titers of 
immunoglobulin against all NPEVs. Of note, immunoglobulin 
replacement might contribute to the relatively short-term excre-
tion of OPV strains observed in some PID patients; however, we 
could not test this phenomenon as all poliovirus excreters in this 
study were receiving IVIG or SCIG treatment.
Poliovirus 2 was the most prevalent serotype detected in 
iVDPV excreting PID patients (80%), followed by serotype 3 
(20%); consistent with the findings in PID patients with paraly-
sis (4, 8). Concurrent infection with more than one iVDPV 
serotype has been documented in other studies; but we did not 
observe simultaneous shedding of more than one iVDPV sero-
type in any patient. Possible explanations for the predominance 
of poliovirus 2 include the high frequency of recombination that 
can occur with poliovirus 1 and 3 in OPV vaccinated individuals, 
resulting in a virus with a higher replication efficiency (23–26). 
Sabin poliovirus 2 also replicates longer and is transmitted more 
readily due to greater replication fitness or the ability to out-
compete the other two serotypes for the binding to the CD155 
receptor in the host cells (27, 28). Although these characteristics 
are potential factors for an increased risk of iVDPV2 in PID, 
they contributed to the eradication of WPV type 2 (29) and 
poliovirus 2 has since been removed from the trivalent OPV 
vaccine (30).
All SCID poliovirus excreters and 50% of MHC class II 
deficient poliovirus excreters became iVDPV excreters. While 
the number of iVDPV excreters was small, this result suggests 
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that cellular immunity may contribute effectively to clearance of 
enterovirus infections including cessation of poliovirus excre-
tion. Both humoral (antigen-specific plasma cells and memory 
B  cells) and cellular (memory T  cells) immunities should be 
developed following an effective immunization especially for 
complex vaccines against viruses. In addition to the capabil-
ity of OPV-infected dendritic cells to engage specific CD8 
T cells, the presence of OPV-specific CD4 T cells in vaccinated 
individuals is crucial. CD4 T  cells are involved in serotype-
specific antibody production (B cell priming by follicular helper 
T  cells) and interferon gamma production to lyse infected 
target cells (virus clearance by cytolytic effector CD4 cells as 
well as cytolytic effector CD8 T cells). Antigen presentation in 
both functions of CD4 T  cells is through MHC class II (31). 
Therefore, patients with combined immunodeficiencies who 
lack both humoral and cellular immunities may be more likely 
to be unable to stop virus excretion. However, the presence of 
six patients with antibody deficiency with long-term poliovirus 
shedding (approximately 9 years) highlights the important role 
of viral specific-antibodies in complete clearance of the virus 
(32). Considering the several reports of antibody deficient 
patients with paralysis caused by iVDPV, the identification and 
treatment of poliovirus symptom-free virus excreting patients 
is necessary (3–5).
Wild poliovirus or iVDPV infections were not observed in 
the patients with a history of the paralytic disease, and none of 
their neurologic symptoms were linked to poliovirus infection. 
Moreover, paralytic disease in the context of PID has several 
potential etiologies including neurologic autoimmune disorders 
including multiple sclerosis, myalgic encephalomyelitis, myas-
thenia gravis, Guillain–Barré syndrome, chronic inflammatory 
demyelinating polyneuropathy, and vasculitic neuropathies. 
Moreover, vitamin deficiency (B12) and paraneoplastic neuropa-
thy should be considered as differential diagnosis for paralysis in 
PID patients (33).
This study provides an estimate of the global iVDPV 
prevalence among PID patients without paralytic disease and 
supports expanded screening for iVDPV excretion in these 
patients. Although most previous studies focused on the risk of 
long-term iVDPV infection in antibody deficient patients, the 
predominance of risk in patients with combined immunodefi-
ciencies included in the current study highlights the importance 
of considering this group of PID patients in any surveillance 
program. Reinfection with poliovirus and NPEV excretion in 
PID patients described elsewhere demonstrates the need for 
prolonged follow-up (17).
The Global Polio Eradication Initiative plans to cease use of 
OPV worldwide once WPV has been certified as eradicated, 
which will end the generation of new iVDPVs. However, there 
is currently no means for addressing the threat posed by existing 
immunodeficient persons infected with iVDPVs, either to the 
infected individual’s risk of paralytic disease, or to the commu-
nity of a continuing source of poliovirus transmission. Antivirals 
represent a potential means to manage the treatment of iVDPV 
excreters and the risk they present to the eradication effort 
(32, 34). Two safe virus-specific antivirals acting by differing 
mechanisms are now being developed and may be used as a 
combination (e.g., pocapavir and V-7404). This strategy may 
resolve the individual’s infection, stop iVDPV excretion, and 
serve to eliminate the risk of poliovirus transmission in the 
community. Currently, pocapavir is being considered for use in 
poliovirus excreting PID patients on a compassionate use basis.
The limitations of the existing study include that no low-
income level country participated, which may bias the generali-
zation of these findings. Moreover, other forms of less profound 
combined immunodeficiency should be evaluated in future 
studies since this study recruited only patients with MHC class II 
deficiency.
The potential risk posed by iVDPV excreters to the polio 
eradication effort indicates the immediate need to develop and 
implement a global iVDPV surveillance strategy. Utilizing this 
approach, individuals at risk of prolonged poliovirus excretion 
can be identified and antiviral treatment can be initiated.
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